Literature DB >> 12867295

Reactivity of agalactosyl IgG with rheumatoid factor.

Yuji Imafuku1, Hiroshi Yoshida, Yuji Yamada.   

Abstract

BACKGROUND: The difference in the reactivity of rheumatoid factor (RF) with agalactosyl IgG and galactosyl or intact IgG is controversial.
METHODS: ELISAs for IgM-RF, using agalactosyl IgG and galactosyl IgG as a coated antigen, were developed. The sera of patients with RA, systemic lupus erythematosus (SLE), chronic liver diseases (CLD) and healthy subjects were measured for IgM-RF. An absorption test was performed using these IgGs with or without heat-pretreatment to determine any differences in the antigenicity between agalactosyl IgG and intact IgG.
RESULTS: IgM-RF titers were higher against agalactosyl IgG than those against both heated-intact and intact IgG in three of nine RA patients' sera. Three other serum samples showed similar titers against all three forms of IgG and the remaining three serum samples showed varied results. IgM-RF titers were higher in sera of RA patients than those of SLE, CLD and healthy subjects. Absorptions of RA sera showed that RF was completely absorbed by 5x of absorptions with agalactosyl IgG as well as intact IgG.
CONCLUSIONS: The reactivity of IgM-RF is higher with agalactosyl IgG than with heated-intact or intact IgG. The antigenic epitopes of agalactosyl and intact IgG were shown to be closely similar by the absorption test.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12867295     DOI: 10.1016/s0009-8981(03)00245-6

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

1.  Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy.

Authors:  J Stümer; M H C Biermann; J Knopf; I Magorivska; A Kastbom; A Svärd; C Janko; R Bilyy; G Schett; C Sjöwall; M Herrmann; L E Muñoz
Journal:  Clin Exp Immunol       Date:  2017-06-13       Impact factor: 4.330

Review 2.  The influence of ACPA status and characteristics on the course of RA.

Authors:  Annemiek Willemze; Leendert A Trouw; René E M Toes; Tom W J Huizinga
Journal:  Nat Rev Rheumatol       Date:  2012-01-31       Impact factor: 20.543

3.  Immunoglobulin G Glycosylation Changes in Aging and Other Inflammatory Conditions.

Authors:  Fabio Dall'Olio; Nadia Malagolini
Journal:  Exp Suppl       Date:  2021

4.  Anti-agalactosyl IgG antibodies in Thai patients with rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis.

Authors:  Worawit Louthrenoo; Nuntana Kasitanon; Ramjai Wichainun; Suparaporn Wangkaew; Waraporn Sukitawut; Shoji Kuwata; Fujio Takeuchi
Journal:  Clin Rheumatol       Date:  2009-11-29       Impact factor: 2.980

Review 5.  Antibody glycosylation in autoimmune diseases.

Authors:  Xing Zhou; Francesca Motta; Carlo Selmi; William M Ridgway; M Eric Gershwin; Weici Zhang
Journal:  Autoimmun Rev       Date:  2021-03-14       Impact factor: 9.754

6.  Clinical severity of visceral leishmaniasis is associated with changes in immunoglobulin g fc N-glycosylation.

Authors:  Luiz Gustavo Gardinassi; Viktoria Dotz; Agnes Hipgrave Ederveen; Roque Pacheco de Almeida; Carlos Henrique Nery Costa; Dorcas Lamounier Costa; Amélia Ribeiro de Jesus; Oleg A Mayboroda; Gustavo Rocha Garcia; Manfred Wuhrer; Isabel Kinney Ferreira de Miranda Santos
Journal:  MBio       Date:  2014-12-02       Impact factor: 7.867

7.  Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study.

Authors:  Fleur E van de Geijn; Manfred Wuhrer; Maurice Hj Selman; Sten P Willemsen; Yaël A de Man; André M Deelder; Johanna Mw Hazes; Radboud Jem Dolhain
Journal:  Arthritis Res Ther       Date:  2009-12-16       Impact factor: 5.156

8.  Abberant Immunoglobulin G Glycosylation in Rheumatoid Arthritis by LTQ-ESI-MS.

Authors:  Zhipeng Su; Qing Xie; Yanping Wang; Yunsen Li
Journal:  Int J Mol Sci       Date:  2020-03-17       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.